BRAF | NRAS | c-KIT | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
mutation | wild type | P | mutation | wild type | P | mutation | wild type | P | ||
129 (56.1%) | 101 (43.9%) | 31 (15.1%) | 174 (84.9%) | 3 (1.5%) | 202 (98.5%) | |||||
Age (years; mean) | 52.3 | 59.3 | 61.4 | 54.7 | 63.4 | 54.9 | ||||
Gender | male | 82 (63.6%) | 59 (58.4%) | 19 (61.3%) | 113 (64.9%) | 2 (66.7%) | 130 (64.4%) | |||
female | 47 (36.4%) | 42 (41.6%) | 12 (38.7%) | 61 (35.1%) | 1 (33.3%) | 72 (35.6%) | ||||
Histological subtypes due to low number of specified groups results should be interpreted carefully | ||||||||||
SSM | 40 (31.0%) | 21 (20.8%) | due to low number of specified groups results should be interpreted carefully | 6 (19.3%) | 46 (26.4%) | due to low number of specified groups results should be interpreted carefully | 0 (0.0%) | 52 (25.7%) | ||
NM | 22 (17.1%) | 23 (22.8%) | 10 (32.3%) | 33 (19.0%) | 2 (66.7%) | 41 (20.3%) | ||||
ALM | 0 (0.0%) | 1 (1.0%) | 0 (0.0%) | 1 (0.6%) | 0 (0.0%) | 1 (0.5%) | ||||
LMM | 1 (0.8%) | 3 (3.0%) | 0 (0.0%) | 3 (1.7%) | 0 (0.0%) | 3 (1.5%) | ||||
other | 3 (2.3%) | 11 (10.9%) | 2 (6.5%) | 9 (5.1%) | 1 (33.3%) | 10 (5.0%) | ||||
NOS | 63 (48.8%) | 42 (41.5%) | 13 (41.9%) | 82 (47.2%) | 0 (0.0%) | 95 (47.0%) | ||||
Site of primary | ||||||||||
head and neck | 12 (9.3%) | 12 (11.9%) | 1 (3.2%) | 21 (12.1%) | 0 (0.0%) | 22 (10.9%) | ||||
trunk | 63 (48.8%) | 28 (27.8%) | 10 (32.2%) | 70 (40.2%) | 1 (33.3%) | 79 (39.1%) | ||||
extremities | 25 (19.4%) | 27 (26.7%) | 12 (38.8%) | 33 (19.0%) | 1 (33.3%) | 44 (21.7%) | ||||
unknown | 27 (20.9%) | 18 (17.8%) | 8 (25.8%) | 35 (20.1%) | 0 (0.0%) | 43 (21.3%) | ||||
mucosal | 0 (0.0%) | 7 (6.9%) | 0 (0.0%) | 7 (4.0%) | 1 (33.3%) | 6 (3.0%) | ||||
uveal | 2 (1.6%) | 9 (8.9%) | 0 (0.0%) | 8 (4.6%) | 0 (0.0%) | 8 (4.0%) | ||||
Initially metastatic disease | ||||||||||
Yes | 36 (27.9%) | 25 (24.8%) | 10 (32.2%) | 47 (27.0%) | 1 (33.3%) | 56 (27.7%) | ||||
No | 93 (72.1%) | 76 (75.2%) | 21 (67.8%) | 127 (73.0%) | 2 (66.7%) | 146 (72.3%) |
Number of patient (N = 230) | % of all patient | |
---|---|---|
Gender | ||
male | 141 | 61.3 |
female | 89 | 38.7 |
Age at the time of diagnosis (years) | ||
< 50 | 78 | 33.9 |
50 – 59 | 58 | 25.2 |
60 – 69 | 55 | 23.9 |
> 69 | 39 | 17.0 |
Location of primary tumour | ||
cutaneous | ||
trunk | 91 | 39.6 |
extremities | 52 | 22.6 |
head and neck | 24 | 10.4 |
uveal | 11 | 4.8 |
mucusal | 7 | 3.0 |
occult | 45 | 19.6 |
Tumour stages at diagnosis | ||
in situ | 1 | 0.4 |
localised | 67 | 29.1 |
regional | 116 | 50.5 |
distant | 46 | 20.0 |
Number of patient (N = 167) | % of all patient | Mean | Range | |
---|---|---|---|---|
Melanoma subtype | ||||
SSM | 61 | 36.6 | ||
NM | 45 | 26.9 | ||
ALM | 1 | 0.6 | ||
LMM | 4 | 2.4 | ||
NOS | 54 | 32.3 | ||
Other | 2 | 1.2 | ||
Clark | 3.8 | (2.0–5.0) | ||
Breslow | 4.8 | (0.2–48.0) | ||
Mitotic index | 8.4 | (0.0–60.0) | ||
Ulceration | 81 | 48.5 |
Number of wild type (%) | Number of mutation (%) | Type | |
---|---|---|---|
BRAF (N = 230) | 101 (43.9%) | 129 (56.1%) | |
114 (49.6%) | V600E: Val600Glu (c.1799T>A) | ||
15 (6.5%) | V600K: Val600Lys (c.1798_1799GT>AA) | ||
NRAS in 25 cases NRAS and c-KIT analysis was not completed due to inadequact tissue samples | 174 (84.9%) | 31 (15.1%) | |
10 (4.9%) | c.181C>A p.(Gln61Lys) | ||
14 (6.7%) | c.182A>G p.(Gln61Arg) | ||
2 (1.0%) | c.182A>T p.(Gln61Leu) | ||
1 (0.5%) | c.34G>T p.(Gly12Cys) | ||
3 (1.5%) | c.37G>C p.(Gly13Arg) | ||
1 (0.5%) | c.183A>C p.(Gln61His) | ||
c-KIT in 25 cases NRAS and c-KIT analysis was not completed due to inadequact tissue samples | 202 (98.5%) | 3 (1.5%) | |
2 (1.0%) | c.1676T>C p.(Val559Ala) | ||
1 (0.5%) | c.1727T>C p.(Leu576Pro) |